Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.73
+0.60 (9.79%)
Mar 10, 2026, 4:08 PM HKT
161.87%
Market Cap 4.82B
Revenue (ttm) 220.66M
Net Income (ttm) -50.02M
Shares Out 786.67M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE 45.12
Dividend n/a
Ex-Dividend Date n/a
Volume 7,099,981
Average Volume 2,480,760
Open 6.18
Previous Close 6.13
Day's Range 6.18 - 6.98
52-Week Range 2.35 - 11.80
Beta 0.60
RSI 57.11
Earnings Date Mar 10, 2026

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, and NSCLC; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C re... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 211
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1167
Full Company Profile

Financial Performance

In 2024, HKG:1167's revenue was 155.71 million, an increase of 145.13% compared to the previous year's 63.52 million. Losses were -155.71 million, -56.64% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.